Therafectin Enters Phase III For RA
Boston Life Sciences has begun a Phase III trial of Therafectin (amiprilose HCl), a candidate drug for the treatment of rheumatoid arthritis, which it acquired as a consequence of its merger with Greenwich Pharmaceuticals in June 1995.
The 20-week, Phase III trial is expected to enroll around 200 RA patients at 10-15 centers in the USA. Boston expects to release the results of the trial sometime in the first half of 1997.
Marc Lanser, chief scientific officer at Boston, said that the company had designed the Phase III trial on the same lines as Greenwich's prior RA-9 study, which gave positive results for Therafectin as a treatment for RA. If the new trial provides similar results, Boston should be in a position to file for approval of the drug, said Dr Lanser.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze